The Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion on 13 October 2010, recommending to grant a variation to the terms of the marketing authorisation for the veterinary medicinal product Circovac.
The change agreed by the CVMP concerns use of the vaccine in a new target category of animals:©piglets.
Detailed conditions for the use of this product will be described in the updated Summary of Product Characteristics (SPC) which will be published in the revised European Public Assessment Report (EPAR) and will be available in all official European Union languages after the variation/extension to the marketing authorisation has been granted by the European Commission.